Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Exploratory and Open Clinical Study of Apatinib Mesylate as First-line Treatment for Advanced Esophagus Cancer.

NCT03542422 is registered in ClinicalTrials.gov with Affiliated Hospital of North Sichuan Medical College as lead sponsor.

NCT NCT03542422
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03542422 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Exploratory and Open Clinical Study of Apatinib Mesylate as First-line Treatment for Advanced Esophagus Cancer.
Lead sponsor
Affiliated Hospital of North Sichuan Medical College
Phase
Phase 2
Overall status
Unknown status
Start date
June 30, 2018
Completion date
May 31, 2019
Enrollment
50 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced esophagus cancer